DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/BF03347261, but it redirected us to https://link.springer.com/article/10.1007/BF03347261. The analysis below is for the second page.

Title[redir]:
Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women | Journal of Endocrinological Investigation
Description:
The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 postmenopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a slight reduction of fat mass in trunk and central region and an increase in legs and, in relation to CG, significantly lower values of adiposity in trunk and abdominal region (p<0.05). At the same time, HDL-cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) were significantly increased in relation to baseline values and CG (p<0.05) and apolipoprotein B (ApoB), total cholesterol/HDL-C, LDL cholesterol/HDL-C, and ApoB/ApoA1 ratios significantly decreased compared to baseline values and CG (p<0.05). No correlation was underlined among lipids and regional fat distribution. These results highlight the positive effect of RLX on lipids and suggest, for the first time, that RLX promotes the shift from android to gynoid fat distribution, and prevents the uptrend of abdominal adiposity and body weight compared with untreated women.

Matching Content Categories {📚}

Health & Fitness
Education
Fitness & Wellness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 80,473,390 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, google, scholar, pubmed, cas, women, raloxifene, postmenopausal, fat, study, effects, distribution, body, risk, med, clin, lipids, diabetes, therapy, healthy, abdominal, disease, heart, bone, lipid, access, cholesterol, cardiovascular, metabolism, estrogen, content, central, factors, menopause, serum, int, replacement, insulin, privacy, cookies, journal, control, group, density, endocrinol, metab, osteoporosis, randomized, data, information,

Topics {✒️}

month download article/chapter open-label clinical study endothelium-de-pendent vasodilation potential harm-hormone therapy healthy post-menopausal women low-density lipoprotein cholesterol high-density lipoprotein cholesterol central obesity long-term fracture prediction full article pdf related subjects american heart association post hoc analysis randomized placebo-controlled study privacy choices/manage cookies total cholesterol/hdl ldl cholesterol/hdl central abdominal fat atherogenic lipid profile hormone replacement therapy european economic area meta-analysis fat cell metabolism endocrinological investigation aims hormonal replacement therapy regional fat distribution gynoid fat distribution cardiovascular risk factors cholesterol-fed rabbits bone mineral density serum lipid levels body fat distribution serum cholesterol concentrations postmenopausal replacement therapy body weight compared coronary heart disease low bone density icarus study group risk factor findings coronary hearth disease fat mass distribution placebo controlled study abdominal fat distribution quebec cardiovascular study scope submit manuscript nutrition examination survey kauffman rf magnetic resonance imaging stroke statistical update long-term effects

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women
         description:The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 postmenopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a slight reduction of fat mass in trunk and central region and an increase in legs and, in relation to CG, significantly lower values of adiposity in trunk and abdominal region (p<0.05). At the same time, HDL-cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) were significantly increased in relation to baseline values and CG (p<0.05) and apolipoprotein B (ApoB), total cholesterol/HDL-C, LDL cholesterol/HDL-C, and ApoB/ApoA1 ratios significantly decreased compared to baseline values and CG (p<0.05). No correlation was underlined among lipids and regional fat distribution. These results highlight the positive effect of RLX on lipids and suggest, for the first time, that RLX promotes the shift from android to gynoid fat distribution, and prevents the uptrend of abdominal adiposity and body weight compared with untreated women.
         datePublished:2014-03-28T00:00:00Z
         dateModified:2014-03-28T00:00:00Z
         pageStart:623
         pageEnd:631
         sameAs:https://doi.org/10.1007/BF03347261
         keywords:
            Raloxifene
            fat distribution
            lipids
            Medicine/Public Health
            general
            Endocrinology
            Metabolic Diseases
            Internal Medicine
         image:
         isPartOf:
            name:Journal of Endocrinological Investigation
            issn:
               1720-8386
               0391-4097
            volumeNumber:28
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:C. M. Francucci
               affiliation:
                     name:University of Ancona
                     address:
                        name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:D. Pantaleo
               affiliation:
                     name:Eli Lilly Italia SpA
                     address:
                        name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Iori
               affiliation:
                     name:Eli Lilly Italia SpA
                     address:
                        name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Camilletti
               affiliation:
                     name:University of Ancona
                     address:
                        name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Massi
               affiliation:
                     name:University of Ancona
                     address:
                        name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Boscaro
               affiliation:
                     name:University of Ancona
                     address:
                        name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women
      description:The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 postmenopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a slight reduction of fat mass in trunk and central region and an increase in legs and, in relation to CG, significantly lower values of adiposity in trunk and abdominal region (p<0.05). At the same time, HDL-cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) were significantly increased in relation to baseline values and CG (p<0.05) and apolipoprotein B (ApoB), total cholesterol/HDL-C, LDL cholesterol/HDL-C, and ApoB/ApoA1 ratios significantly decreased compared to baseline values and CG (p<0.05). No correlation was underlined among lipids and regional fat distribution. These results highlight the positive effect of RLX on lipids and suggest, for the first time, that RLX promotes the shift from android to gynoid fat distribution, and prevents the uptrend of abdominal adiposity and body weight compared with untreated women.
      datePublished:2014-03-28T00:00:00Z
      dateModified:2014-03-28T00:00:00Z
      pageStart:623
      pageEnd:631
      sameAs:https://doi.org/10.1007/BF03347261
      keywords:
         Raloxifene
         fat distribution
         lipids
         Medicine/Public Health
         general
         Endocrinology
         Metabolic Diseases
         Internal Medicine
      image:
      isPartOf:
         name:Journal of Endocrinological Investigation
         issn:
            1720-8386
            0391-4097
         volumeNumber:28
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:C. M. Francucci
            affiliation:
                  name:University of Ancona
                  address:
                     name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:D. Pantaleo
            affiliation:
                  name:Eli Lilly Italia SpA
                  address:
                     name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Iori
            affiliation:
                  name:Eli Lilly Italia SpA
                  address:
                     name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Camilletti
            affiliation:
                  name:University of Ancona
                  address:
                     name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Massi
            affiliation:
                  name:University of Ancona
                  address:
                     name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Boscaro
            affiliation:
                  name:University of Ancona
                  address:
                     name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Endocrinological Investigation
      issn:
         1720-8386
         0391-4097
      volumeNumber:28
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Ancona
      address:
         name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
         type:PostalAddress
      name:Eli Lilly Italia SpA
      address:
         name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
         type:PostalAddress
      name:Eli Lilly Italia SpA
      address:
         name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
         type:PostalAddress
      name:University of Ancona
      address:
         name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
         type:PostalAddress
      name:University of Ancona
      address:
         name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
         type:PostalAddress
      name:University of Ancona
      address:
         name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:C. M. Francucci
      affiliation:
            name:University of Ancona
            address:
               name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:D. Pantaleo
      affiliation:
            name:Eli Lilly Italia SpA
            address:
               name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
               type:PostalAddress
            type:Organization
      name:N. Iori
      affiliation:
            name:Eli Lilly Italia SpA
            address:
               name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
               type:PostalAddress
            type:Organization
      name:A. Camilletti
      affiliation:
            name:University of Ancona
            address:
               name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
               type:PostalAddress
            type:Organization
      name:F. Massi
      affiliation:
            name:University of Ancona
            address:
               name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
               type:PostalAddress
            type:Organization
      name:M. Boscaro
      affiliation:
            name:University of Ancona
            address:
               name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
      name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
      name:Medical Department, Eli Lilly Italia SpA, Florence, Italy
      name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
      name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
      name:Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(226)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

6.32s.